SAN
DIEGO, June 1, 2023 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene
therapy company advancing a new class of treatments for patients
with cancer and rare diseases, today announced that its virtual
Annual Meeting of Stockholders (the "Annual Meeting") will be held
on Thursday, June 15, 2023 at
1:00 p.m. PT.
The Annual Meeting will be held through a live webcast.
Stockholders of record at the close of business on April 19, 2023, are entitled to vote in the
Annual Meeting.
As provided in the Company's proxy materials, an online portal
is available to stockholders at
https://www.proxydocs.com/PSTX where stockholders can view and
download the Company's proxy materials and 2022 Annual Report and
vote their shares in advance of the Annual Meeting. Stockholders
may also submit questions and vote their shares prior to the Annual
Meeting by following the instructions available on the Annual
Meeting website.
To be admitted to the Annual Meeting, stockholders must register
by 8:00 p.m. PT on June 13, 2023 at https://www.proxydocs.com/PSTX.
To register, stockholders must enter the control number found on
the proxy card in the materials sent to stockholders. After
registration is complete, further instructions including a unique
link to access the virtual Annual Meeting will be emailed.
Poseida encourages stockholders to access the Annual Meeting
prior to the start time in order to allow ample time for check-in
procedures.
Below are additional details on how stockholders can participate
in the virtual Annual Meeting:
- Access the Annual Meeting website beginning at 12:45 p.m. PT on June 15,
2023.
- Vote during the Annual Meeting by following the instructions
available on the Annual Meeting website.
- Submit a question in advance of the meeting by visiting the
Annual Meeting website and entering the stockholder's control
number.
Whether or not a stockholder plans to attend the virtual-only
Annual Meeting, Poseida Therapeutics urges each stockholder to vote
and submit their proxy in advance of the meeting by one of the
methods described in the proxy materials.
About Poseida Therapeutics, Inc.
Poseida Therapeutics
is a clinical-stage biopharmaceutical company advancing
differentiated cell and gene therapies with the capacity to cure
certain cancers and rare diseases. The Company's pipeline includes
allogeneic CAR-T cell therapy product candidates for both solid and
liquid tumors as well as in vivo gene therapy product candidates
that address patient populations with high unmet medical need. The
Company's approach to cell and gene therapies is based on its
proprietary genetic editing platforms, including its non-viral
piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene
Editing System and nanoparticle and hybrid gene delivery
technologies. The Company has formed global strategic
collaborations with Roche and Takeda to unlock the promise of cell
and gene therapies for patients. Learn more at www.poseida.com and
connect with us on Twitter and LinkedIn.
Investor contact:
Alex
Lobo
Managing Director
Stern Investor Relations
IR@poseida.com
Media contact:
Sarah
Thailing
Senior Director, Corporate Communications and IR
Poseida Therapeutics
PR@poseida.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-virtual-2023-annual-meeting-of-stockholders-301839392.html
SOURCE Poseida Therapeutics, Inc.